NCT06072781
VS-6766-301/GOG-3097 A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Associated Conditions
Ovarian, Fallopian, or Primary Peritoneum CancerSponsor
Verastem & GOG Partners
This study is currently enrolling.